Low-Dose (15 mg/day) Pioglitazone Treatment Improves Glycemic Control, and Whole-Body and Adipocyte Insulin Resistance With Minimal Weight Gain in Type 2 Diabetic Subjects

被引：0
|
作者：
Perez-Cadena, Zandra
Daniele, Giuseppe
Chavez, Alberto
Kamath, Subhash
Zuo, Pengou
Chang, Zhi
Andreozzi, Francesco
Paez, Ana
Winnier, Deidre
Arya, Ruth
Hansis-Diarte, Andrea
Cortez, Lauren
Jenkinson, Christopher
Fanti, Paolo
Gastaldelli, Amalia
Defronzo, Ralph
Tripathy, Devjit
Folli, Franco
机构：
来源：
DIABETES | 2012年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1090-P
引用
收藏
页码：A281 / A281
页数：1
相关论文
共 21 条
  • [1] Low-dose pioglitazone improves glycaemic control, whole-body, and adipocyte insulin resistance, and reduces plasma fractalkine, a novel cytokine in type 2 diabetes
    Tripathy, D.
    Daniele, G.
    Perez-Cadena, Z.
    Chavez, A.
    Kamath, S.
    Andreozzi, F.
    Fiorentino, T. V.
    Gastaldelli, A.
    De Fronzo, R.
    Folli, F.
    DIABETOLOGIA, 2012, 55 : S326 - S326
  • [2] Low-Dose (15 mg/day) Pioglitazone Treatment Improves Glycemic and Sub-Inflammatory State in Obese Type 2 Diabetic Subjects in 24 Week Intervention Study
    Daniele, Giuseppe
    Perez-Cadena, Zandra
    Chavez-Velasquez, Alberto
    Kamath, Subhash
    Zuo, Penguo
    Chang, Zhi
    Andreozzi, Francesco
    Paez, Ana M.
    Fourcaudot, Marcel
    Winnier, Deidre
    Arya, Ruth
    Hansis-Diarte, Andrea
    Jenkinson, Christopher
    Fanti, Paolo
    Gastaldelli, Amalia
    Defronzo, Ralph
    Tripathy, Devjit
    Folli, Franco
    DIABETES, 2012, 61 : A274 - A274
  • [3] Effects of low-dose growth hormone on body composition, insulin resistance, and glycemic control in obese type 2 diabetic patients
    Kim, DM
    Ahn, CW
    Cha, BS
    Lim, SK
    Kim, KR
    Lee, HC
    INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 : S155 - S155
  • [4] Combined treatment with low-dose pioglitazone and beraprost sodium improves glucose intolerance without causing body weight gain
    Kumagai H.
    Kubota N.
    Kubota T.
    Takahashi T.
    Inoue M.
    Kawai T.
    Iwayama K.
    Moroi M.
    Sugi K.
    Kadowaki T.
    Diabetology International, 2013, 4 (4) : 226 - 232
  • [5] Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus
    Majima, Takafumi
    Komatsu, Yasato
    Doi, Kentaro
    Shigemoto, Michika
    Takagi, Chieko
    Fukao, Atsushi
    Corners, Jerry
    Nakao, Kazuwa
    ENDOCRINE JOURNAL, 2006, 53 (03) : 325 - 330
  • [6] Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes
    Aso, Yoshimasa
    Hara, Kenji
    Ozeki, Noriyuki
    Yatsuka, Chikako
    Nakano, Tomoki
    Matsumoto, Sachiko
    Suetsugu, Mariko
    Nakamachi, Takafumi
    Takebayashi, Kohzo
    Haruki, Kohsuke
    Inukai, Toshihiko
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2009, 85 (02) : 147 - 152
  • [7] Effect of low dose pioglitazone on glycemic control and insulin resistance in Type 2 diabetes: A randomized, double blind, clinical trial
    Rajagopalan, Sujit
    Dutta, Pinaki
    Hota, Debasish
    Bhansali, Anil
    Srinivasan, Anand
    Chakrabarti, Amitava
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 109 (03) : E32 - E35
  • [8] Liraglutide Reverses Pronounced Insulin-Associated Weight Gain, Improves Glycemic Control, and Decreases Insulin Dose in Patients with Type 2 Diabetes
    De Wit, Helena
    Vervoort, Gerald M.
    Jansen, Henry J.
    De Grauw, Wim J. C.
    De Galan, Bastiaan E.
    Tack, Cees J.
    DIABETES, 2014, 63 : A249 - A250
  • [9] Improved plasma glucose control, whole-body glucose utilization, and lipid profile on a low-glycemic index diet in type 2 diabetic men
    Rizkalla, SW
    Taghrid, L
    Laromiguiere, M
    Huet, D
    Boillot, J
    Rigoir, A
    Elgrably, F
    Slama, G
    DIABETES CARE, 2004, 27 (08) : 1866 - 1872
  • [10] 26. Liraglutide Reverses Pronounced Insulin-Associated Weight Gain, Improves Glycemic Control, and Decreases Insulin Dose in Patients with Type 2 Diabetes (973-P)
    Helena de Wit
    Gerald M. Vervoort
    Henry J. Jansen
    Wim J.C. de Grauw
    Bastiaan E. de Galan
    Cees J. Tack
    Nederlands Tijdschrift voor Diabetologie, 2014, 12 (4) : 29 - 29
123